Jazz Pharmaceuticals, Inc. (JAZZ)
NASDAQ · Manufacturing · Pharmaceutical preparations
$237.95+$1.67 (+0.71%) on the dayAs of the close; data may be delayed.
JAZZ price, last 12 months
Key stats
- Previous close
- $236.28
- Open
- $236.28
- Day range
- $235.66 – $239.12
- 52-week range
- $125.79 – $266.38
- Volume
- 816.6K
- Avg volume (20 days)
- 775.7K
- Market cap
- $15.4B
Performance
1W−1.2%
1M−4.6%
3M+3.5%
6M+25.8%
YTD+40.0%
1Y+83.6%
vs S&P 500, 1Y+66.8 pts
Technicals and fundamentals
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $15.4B